Early next year, the U.S. biotech start-up Loyal anticipates the release of LOY-002, a daily pill designed to give dogs at least one extra year of healthy life.
This San Francisco-based enterprise has secured a staggering $125 million in funding from companies that were previously hesitant to invest in human longevity projects due to their potentially lengthy timelines.
Celine Halioua, founder and CEO of Loyal, which is under the umbrella of Cellular Longevity, suggests this endeavor could also benefit our species.
“Finding out how to prevent canine age-related decline is a really strong proxy for doing the same with humans because dogs get similar age-related diseases, and share our environments and habits in ways laboratory mice do not,” explained Halioua.
The LOY-002 pill aims to address metabolic changes tied to aging. It will reduce frailty by controlling age-related insulin increases.
“We’re not making immortal dogs. The way the drug extends lifespan, we hypothesise, is by extending health and thus shortening the rate of aging,” said Halioua.
https://www.earth.com/news/longevity-pills-for-dogs-could-help-humans-live-longer-too/
🚨 STUDY: AGE REVERSAL PILL SHOWS PROMISING RESULTS IN DOGS, HUMAN TRIALS NEXT
A groundbreaking study on age reversal, involving a new drug aimed at lengthening telomere caps on stem cells, has shown remarkable results in dogs.
Zeus, a 12-year-old German Shepherd with terminal… pic.twitter.com/0hLI4qiVK1
— Mario Nawfal (@MarioNawfal) August 17, 2024